Initial efforts to broadly improve cholinergic transmission and enhance cognitive function in AD focused on acetylcholinesterase (AChE) inhibitors (e.g., tacrine, physostigmine, and donepezil; for detailed review, see (19). Here, ACHE is linked to Alzheimer disease.